Please assess the completion status of the following clinical trial:

Trial Title: Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~In order to be eligible to participate in this study, the patients must meet all of the following criteria:~1. At least 18 years of age~2. Confirmed COVID-19 disease (by Cobas SARS-CoV-2 real time reverse transcription polymerase chain reaction (RT-PCR) using nasopharyngeal swab sample, or equivalent test available to be performed by the Columbia University Irving Medical Center (CUIMC)/New York Presbyterian (NYP) clinical laboratory). Effort will be made to have the confirmatory test result \<72 hours prior to enrollment however given overall clinical demand this may not be feasible in all cases.~3. Respiratory failure manifesting as: Acute Respiratory Distress Syndrome (defined by a P/F ratio of \<200), OR oxygen saturation (SpO2) \< 90% on 4 liters (L) (actual or expected given higher O2 requirement) OR increasing O2 requirements over 24 hours, plus 2 or more of the following predictors for severe disease:~   CRP \> 35 mg/L Ferritin \> 500 ng/mL D-dimer \> 1 mcg/L Neutrophil-Lymphocyte Ratio \> 4 Lactate dehydrogenase (LDH) \> 200 U/L Increase in troponin in patient w/out known cardiac disease~4. Has a consent designee willing to provide informed consent on behalf of the patient (this assumes that a mechanically ventilated patients lacks capacity to consent on his/her own behalf. Should it be deemed that the patient has capacity to consent, consent may be obtained from the patient.)~5. Women of childbearing potential must be willing and able to use at least one highly effective contraceptive method for a period of 5 months following the study drug administration. In the context of this study, an effective method is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly such as:~   1. combined (estrogen and progestogen containing) hormonal contraception combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, or transdermal)~  2. progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)~  3. intrauterine device (IUD)~  4. intrauterine hormone-releasing system (IUS)~  5. vasectomized partner~  6. bilateral tubal occlusion~  7. true abstinence. when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence, such as calendar, ovulation, symptothermal, postovulation methods, and withdrawal are not acceptable methods of contraception.~6. Men must be willing to use a double-barrier contraception from enrollment until at 5 months after the last dose of study drug, if not abstinent.~Exclusion Criteria:~An individual who meets any of the following criteria will be excluded from participation in this study:~1. Evidence of irreversible injury deemed non-survivable even if the pulmonary failure recovers (for example severe anoxic brain injury)~2. Known active inflammatory bowel disease~3. Known active, untreated diverticulitis~4. Known untreated bacteremia~5. Pregnancy. (The protocol will exclude pregnant subjects given the lack of overall data on use of clazakizumab in pregnancy however the study team would consider a protocol revision should more than 3 potential pregnant study subjects be excluded on this basis).~6. Known hypersensitivity to the clazakizumab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clazakizumab 25 mg (Type: EXPERIMENTAL): The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum C-reactive protein (CRP) will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.
- Placebo (Type: PLACEBO_COMPARATOR): The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).